Home >> Research Area >>Natural Products>>Coumarins>> Meranzin hydrate

Meranzin hydrate

CAS# 5875-49-0

Meranzin hydrate

Catalog No. BCN5798----Order now to get a substantial discount!

Product Name & Size Price Stock
Meranzin hydrate:5mg Please Inquire In Stock
Meranzin hydrate:10mg Please Inquire In Stock
Meranzin hydrate:20mg Please Inquire In Stock
Meranzin hydrate:50mg Please Inquire In Stock

Quality Control of Meranzin hydrate

Number of papers citing our products

Chemical structure

Meranzin hydrate

3D structure

Chemical Properties of Meranzin hydrate

Cas No. 5875-49-0 SDF Download SDF
PubChem ID 821434 Appearance Powder
Formula C15H18O5 M.Wt 278.3
Type of Compound Coumarins Storage Desiccate at -20°C
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Chemical Name 8-[(2S)-2,3-dihydroxy-3-methylbutyl]-7-methoxychromen-2-one
SMILES CC(C)(C(CC1=C(C=CC2=C1OC(=O)C=C2)OC)O)O
Standard InChIKey KGGUASRIGLRPAX-LBPRGKRZSA-N
Standard InChI InChI=1S/C15H18O5/c1-15(2,18)12(16)8-10-11(19-3)6-4-9-5-7-13(17)20-14(9)10/h4-7,12,16,18H,8H2,1-3H3/t12-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Meranzin hydrate

The roots of Angelica biserrata

Biological Activity of Meranzin hydrate

Description1. Meranzin hydrate produces a rapid effect mediated by AMPA receptors and involving BDNF modulation through the ERK1/2 pathway. 2. Chronic mild stress accelerates the absorption of Meranzin hydrate in rats following the oral administration of Chaihu-Shugan-San. 3. Meranzin hydrate can induce similar effect to Fructus Aurantii on intestinal motility and it was, at least in part, mediated by stimulation of H1 histamine receptors. 4. Meranzin hydrate exhibits antidepressive and prokinetic-like effects through the regulation of the common mediator, the alpha 2-adrenoceptor , and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors.
TargetsAdrenergic Receptor | ERK

Meranzin hydrate Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Meranzin hydrate Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Meranzin hydrate

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.5932 mL 17.9662 mL 35.9324 mL 71.8649 mL 89.8311 mL
5 mM 0.7186 mL 3.5932 mL 7.1865 mL 14.373 mL 17.9662 mL
10 mM 0.3593 mL 1.7966 mL 3.5932 mL 7.1865 mL 8.9831 mL
50 mM 0.0719 mL 0.3593 mL 0.7186 mL 1.4373 mL 1.7966 mL
100 mM 0.0359 mL 0.1797 mL 0.3593 mL 0.7186 mL 0.8983 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Meranzin hydrate

The involvement of AMPA-ERK1/2-BDNF pathway in the mechanism of new antidepressant action of prokinetic meranzin hydrate.[Pubmed:22782214]

Amino Acids. 2013 Feb;44(2):413-22.

It was recently discovered that ketamine can relieve depression in a matter of hours through an action on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. This is much more rapid than the several weeks required for the available antidepressants to show therapeutic efficacy. However, ketamine has negative side effects. The aim of this study was to determine whether the natural prokinetic drug Meranzin hydrate (MH) has a fast-acting antidepressant effect mediated by AMPA receptors. By means of in vivo and in vitro experiments, we found that (1) treatment of rats with MH at 9 mg/kg decreased immobility time in a forced swimming test (FST), as did the popular antidepressant fluoxetine and the AMPA receptor positive modulator aniracetam. Pretreatment of rats with NBQX (10 mg/kg), an antagonist of AMPA receptors, blocked this effect of MH. (2) MH increased number of crossings of forced swimming rats in the open field test. (3) FST enhanced hippocampal ERK1/2, p-ERK1/2 and BDNF expression levels. MH (9 mg/kg) treatment further up-regulated hippocampal p-ERK1/2 and BDNF expression levels, and this effect was prevented by NBQX. (4) MH-increased BDNF expression corresponded with MH-decreased immobility time in the FST. (5) In vitro experiments, we found that incubation of rats hippocampus slices with MH (10, 20 muM respectively) increased concentrations of BDNF and p-ERK1/2. This effect of MH (20 muM) were prevented by NBQX. In conclusion, in animals subjected to acute stress, the natural prokinetic drug MH produced a rapid effect mediated by AMPA receptors and involving BDNF modulation through the ERK1/2 pathway.

Pharmacokinetic study of the prokinetic compounds meranzin hydrate and ferulic acid following oral administration of Chaihu-Shugan-San to patients with functional dyspepsia.[Pubmed:21605652]

J Ethnopharmacol. 2011 Sep 1;137(1):205-13.

AIM OF THE STUDY: The prokinetic activity of ferulic acid derived from Ligusticum chuanxiong hort in the Chaihu-Shugan-San formula has been shown to be similar to Chaihu-Shugan-San, a popular traditional Chinese medicine for treating functional dyspepsia. The effects of Meranzin hydrate, a compound isolated from Fructus aurantii in the Chaihu-Shugan-San formula, are unclear, as the pharmacokinetics have never been studied in patients with functional dyspepsia. This study aimed to describe the pharmacokinetics of ferulic acid and merazin hydrate by evaluating the prokinetics induced by Chaihu-Shugan-San and Meranzin hydrate. MATERIALS AND METHODS: Gastric emptying and intestinal transit were measured after oral administration of a single dose of Chaihu-Shugan-San or Meranzin hydrate in rats. The tone of rat ileum was selected as direct evidence of the prokinetic activity of Meranzin hydrate. Patients with functional dyspepsia were recruited, and Meranzin hydrate and ferulic acid were identified by ultra performance liquid chromatography with tandem mass spectrometry in the plasma of patients following a single oral administration of Chaihu-Shugan-San. The resulting pharmacokinetic properties were determined by ultra performance liquid chromatography coupled to photo diode array. RESULTS: In rats, single doses of Chaihu-Shugan-San (20 g/kg) and Meranzin hydrate (28 mg/kg) significantly accelerated gastric emptying and intestinal transit (Chaihu-Shugan-San: 68.9 +/- 5.6% and 72.3 +/- 4.7%, Meranzin hydrate: 72.9 +/- 3.8% and 75.2 +/- 3.1%) compared with the control (55.45 +/- 3.7% and 63.51 +/- 5.1%, P<0.05), showing similar results as cisapride (69.6 +/- 4.8% and 71.6 +/- 6.3%). Meranzin hydrate (30, 100 mumol/L) directly increased the amplitude of rat ileum compared with the control (P<0.01). The pharmacokinetics profiles of Meranzin hydrate and ferulic acid in patient plasma was fitted with a two-compartment model detected by a simple, rapid and accurate UPLC method. Time to reach peak concentration of Meranzin hydrate (0.371 mg/L) and ferulic acid (0.199 mg/L) was 23.57 min and 27.50 min, respectively. The elimination half-life and area under the concentration-time curve from t=0 to the last time of Meranzin hydrate and ferulic acid were 139.53 min and 31.445 mug min/mL and 131.27 min and 14.835 mug min/mL, respectively. The absorption constant and volume of distribution of Meranzin hydrate and ferulic acid were 0.185 +/- 0.065 min(-1) and 3782.89 +/- 2686.72 L/kg and 0.524 +/- 0.157 min(-1) and 11713 +/- 7618.68 L/kg, respectively. The experimental results of the pharmacokinetic parameters of Meranzin hydrate and ferulic acid indicate that they were absorbed and distributed rapidly. CONCLUSIONS: The pharmacodynamics and pharmacokinetics of prokinetic Chaihu-Shugan-San and its compounds are useful for monitoring Chaihu-Shugan-San formulas in clinical practice and for understanding therapeutic mechanisms.

Meranzin hydrate induces similar effect to Fructus Aurantii on intestinal motility through activation of H1 histamine receptors.[Pubmed:21061180]

J Gastrointest Surg. 2011 Jan;15(1):87-96.

This experiment studied the potential effect of Meranzin hydrate (MH) and decoction of herb Fructus Aurantii (FA) on rat gut motility. It also investigated the prokinetic mechanism of MH. Experiments were performed on male Sprague-Dawley rats (200-220 g). The study included: (1) qualitation of MH and four other known compounds in FA and jejunum after oral administration of FA decoction to rats; (2) in vitro experiment of MH on rat jejunum contractions; (3) in vivo experiment of FA and MH in rats. Dose-dependently, MH (1-100 muM) increased amplitude in longitudinal and circular jejunum muscles. Pretreatment of jejunum longitudinal strips with benzhydramine (1 muM) remarkably inhibited the contractions induced by histamine (1 muM) and MH (10 or 30 muM). Pretreatment of jejunum longitudinal strips with atropine (1 muM) reduced the contractions induced by acetylcholine (1 muM) but did not influence the contractions induced by MH (10 or 30 muM). Interestingly, the antagonism of benzhydramine to MH was also verified in vivo. MH can be absorbed into the jejunum following oral administration of FA decoction. In healthy rats, MH (7, 14, and 28 mg/kg) and FA (3.3, 10, and 20 g/kg) both promoted intestinal transit and gastric emptying in a dose-dependent manner when gavaged acutely. In cisplatin model rats, MH (14 and 28 mg/kg) significantly reversed cisplatin-induced delay in gastric emptying. Meranzin hydrate can induce similar effect to Fructus Aurantii on intestinal motility and it was, at least in part, mediated by stimulation of H1 histamine receptors.

Comparison between the pharmacokinetics of meranzin hydrate in a rat model of chronic depression and in controls following the oral administration of Chaihu-Shugan-San.[Pubmed:24137289]

Exp Ther Med. 2013 Oct;6(4):913-918.

Previous studies have shown that Meranzin hydrate (MH) may be beneficial in depressive disorders. However, to the best of our knowledge, the pharmacokinetic characteristics of MH in depression have not previously been investigated. Chronic mild stress (CMS) in rats is used as a model of depression. The present study was designed to evaluate and compare the pharmacokinetics of MH in CMS and control rats following the oral administration of Chaihu-Shugan-San (CSS). Rats were randomly divided into CMS and control groups and blood samples were obtained following the oral administration of CSS. The quantification of MH levels in the plasma for pharmacokinetic study was achieved using a simple and rapid ultra-performance liquid chromatography with photodiode array (UPLC-PDA) method. Following the oral administration of CSS to CMS rats and controls, the maximum plasma concentration (Cmax) of MH was 58.66+/-6.64 and 57.54+/-12.67 ng/ml at 108.00+/-26.83 and 54.00+/-8.22 min, respectively. Compared with the value of the area under the concentration-time curve (AUC)0-1440 in control rats (19,896.76+/-1,041.95 mug.min/l), the AUC0-1440 value was reduced in CMS rats (18,401.32+/-4332.65 mug.min/l). There were no significant differences in the majority of the pharmacokinetic parameters of MH, including the values for Cmax, AUC0-1440, clearance rate (CL/F) and mean residence time (MRT0-1440), between the CMS rats and the controls. However, the pharmacokinetic parameters showed that CMS accelerated the absorption of MH in rats following the oral administration of CSS.

Meranzin hydrate exhibits anti-depressive and prokinetic-like effects through regulation of the shared alpha2-adrenoceptor in the brain-gut axis of rats in the forced swimming test.[Pubmed:23063894]

Neuropharmacology. 2013 Apr;67:318-25.

BACKGROUND: In recent years, the brain-gut axis theory has received increasing attention in studies of depression. However, most studies separately address potential antidepressant and prokinetic treatments. Investigations of drugs that could potentially treat comorbid depression and gastrointestinal (GI) dysfunction via a common mechanism of action have not yet been performed in detail. AIM: To find a common mechanism of action of our patented drug, Meranzin hydrate (MH), in the antidepressant and prokinetic treatment. METHODS: The forced swimming test (FST) model of depression, plasma ghrelin measurement, and in vivo and in vitro measurements of GI motility were used. RESULTS: 1. Administration of MH (9 mg/kg) decreased the immobility time during the FST after acute treatment; this effect was inhibited by the alpha 2-adrenoceptor antagonist, yohimbine, but not by the alpha 1-adrenoceptor antagonist, prazosin. 2. After chronic treatment, the immobility time of rats during the FST was decreased significantly by MH (2.25 mg/kg). 3. MH (9 mg/kg) increased plasma ghrelin levels in rats subjected to the FST; this increase was enhanced by the ghrelin receptor agonist, GHRP-6. 4. MH (9 mg/kg) also promoted gastric emptying and intestinal transit in rats with or without FST. 5. In vitro, MH (10 muM) increased jejunal contractions in rats subjected to the FST; this effect was inhibited by yohimbine. Furthermore, the inhibitory effect of yohimbine was partly reversed by the ghrelin receptor agonist, GHRP-6. CONCLUSION: Our study revealed that MH from natural resources exhibits antidepressive and prokinetic-like effects through the regulation of the common mediator, the alpha 2-adrenoceptor.

Description

Meranzin hydrate, an absorbed bioactive compound from the Traditional Chinese Medicine (TCM) Chaihu-Shugan-San (CSS), possess anti-depression and anti-atherosclerosis effects.

Keywords:

Meranzin hydrate,5875-49-0,Natural Products, buy Meranzin hydrate , Meranzin hydrate supplier , purchase Meranzin hydrate , Meranzin hydrate cost , Meranzin hydrate manufacturer , order Meranzin hydrate , high purity Meranzin hydrate

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: